GlassScriptPhysician profile
Jennifer Lyn King
NPI 1477958494
$1,002.54
in general payments reported to CMS, 2019-2025
22 companies · $148 in 2025
The $148 reported for 2025 was less than what a typical Family provider received nationally (typical 2025 total: $167).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $15.97 · 2022: $438 · 2023: $364 · 2024: $36.54 · 2025: $148.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $549.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $548.51 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Vanda Pharmaceuticals INC. | $116.03 | 2022 | |
| Otsuka America Pharmaceutical, INC. | $106.93 | 2022-2023 | Rexulti |
| Sanofi-Aventis U.S. LLC | $79.22 | 2022-2023 | |
| Bayer Healthcare Pharmaceuticals INC. | $75.73 | 2022-2023 | |
| Exact Sciences Corporation | $58.65 | 2023 | Cologuard Collection Kit |
| Abbvie INC. | $58.21 | 2023-2025 | |
| Astrazeneca Pharmaceuticals LP | $57.15 | 2022-2025 | Farxiga, Airsupra |
| Amgen INC. | $50.68 | 2025 | Evenity, Prolia |
| Pfizer INC. | $48.76 | 2023 | |
| Medtronic, INC. | $44.77 | 2022 | |
| Novo Nordisk INC | $43.39 | 2022-2025 | Ozempic, Rybelsus |
| Janssen Pharmaceuticals, INC | $42.78 | 2022-2023 | Spravato |
| Boehringer Ingelheim Pharmaceuticals, INC. | $42.67 | 2022-2023 | Synjardy, Jardiance, Tradjenta |
| Astellas Pharma US INC | $36.54 | 2024 | Veozah |
| E.R. Squibb & Sons, L.L.C. | $29.73 | 2021-2022 |
Show all 22 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novartis Pharmaceuticals Corporation | $20.98 | 2025 | |
| Lilly USA, LLC | $19.83 | 2025 | Zepbound |
| Abbott Laboratories | $17.21 | 2023 | Eterna |
| Lucid Diagnostics INC. | $15.76 | 2022 | |
| Glaxosmithkline, LLC. | $15.42 | 2022 | |
| Alnylam Pharmaceuticals INC. | $12.26 | 2022 | |
| Corium, LLC | $9.84 | 2023 | Azstarys |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Jennifer King listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.